NeoGenomics (NEO) Expected to Release Earnings on Wednesday

NeoGenomics (NASDAQ:NEO) will likely be releasing its Q3 2026 results after the market closes on Wednesday, October 28th. Analysts expect NeoGenomics to post earnings of $0.0555 per share and revenue of $206.70 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, October 28, 2026 at 4:30 PM ET.

NeoGenomics (NASDAQ:NEO) last released its earnings results on Tuesday, July 28th. The medical research company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of $0.03 by $0.02. The firm had revenue of $201.66 million during the quarter, compared to analyst estimates of $196.93 million. NeoGenomics had a negative net margin of 6.77% and a negative return on equity of 1.99%. The business’s quarterly revenue was up 11.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.03 EPS. On average, analysts expect NeoGenomics to post ($0.09) EPS for the current fiscal year and $0.05 EPS for the next fiscal year.

NeoGenomics Stock Performance

Shares of NeoGenomics stock opened at $16.59 on Monday. The firm has a fifty day moving average of $17.59 and a two-hundred day moving average of $13.75. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.35 and a current ratio of 3.60. The stock has a market capitalization of $2.13 billion, a price-to-earnings ratio of -41.47 and a beta of 1.79. NeoGenomics has a 52 week low of $7.07 and a 52 week high of $20.15.

Analyst Ratings Changes

A number of equities research analysts recently commented on NEO shares. Needham & Company LLC lifted their price objective on NeoGenomics from $19.00 to $22.00 and gave the stock a “buy” rating in a research note on Tuesday, October 6th. Benchmark increased their target price on NeoGenomics from $11.00 to $16.00 and gave the company a “buy” rating in a research note on Friday, July 24th. Piper Sandler reissued an “overweight” rating on shares of NeoGenomics in a research note on Wednesday, October 7th. TD Cowen restated a “buy” rating on shares of NeoGenomics in a report on Wednesday, July 15th. Finally, Zacks Research lowered NeoGenomics from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 28th. Six research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $18.17.

NeoGenomics Company Profile

NeoGenomics, Inc (NASDAQ: NEO) is a cancer-focused diagnostics company that provides laboratory testing and related services to oncologists, hospitals, academic institutions, and biopharmaceutical companies. Its diagnostic offerings support the detection, classification, and monitoring of cancer and help inform treatment decisions.

The company’s services include pathology, immunohistochemistry, flow cytometry, cytogenetics, molecular testing, and other specialized oncology assays. NeoGenomics also provides clinical trial and pharmaceutical services, including biomarker testing, central laboratory support, and companion diagnostic development for drug developers.

Founded in 1999, NeoGenomics has expanded through internal growth and acquisitions and operates a network of clinical laboratories serving customers primarily in the United States, with additional international capabilities.